MIME-Version: 1.0
Content-Type: multipart/related; boundary="----=_NextPart_01D6175F.3B6735C0"

Данный документ является веб-страницей в одном файле, также называемой файлом веб-архива.  Если вы видите это сообщение, значит данный обозреватель или редактор не поддерживает файлы веб-архива.  Загрузите обозреватель, поддерживающий веб-архивы, например Microsoft Internet Explorer.

------=_NextPart_01D6175F.3B6735C0
Content-Location: file:///C:/68135086/UA105300101_E2BF.htm
Content-Transfer-Encoding: quoted-printable
Content-Type: text/html; charset="windows-1251"

<html xmlns:v=3D"urn:schemas-microsoft-com:vml"
xmlns:o=3D"urn:schemas-microsoft-com:office:office"
xmlns:w=3D"urn:schemas-microsoft-com:office:word"
xmlns:st1=3D"urn:schemas-microsoft-com:office:smarttags"
xmlns=3D"http://www.w3.org/TR/REC-html40">

<head>
<meta http-equiv=3DContent-Type content=3D"text/html; charset=3Dwindows-125=
1">
<meta name=3DProgId content=3DWord.Document>
<meta name=3DGenerator content=3D"Microsoft Word 11">
<meta name=3DOriginator content=3D"Microsoft Word 11">
<link rel=3DFile-List href=3D"UA105300101_E2BF.files/filelist.xml">
<link rel=3DEdit-Time-Data href=3D"UA105300101_E2BF.files/editdata.mso">
<!--[if !mso]>
<style>
v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style>
<![endif]-->
<title>ІНСТРУКЦІЯ</title>
<o:SmartTagType namespaceuri=3D"urn:schemas-microsoft-com:office:smarttags"
 name=3D"metricconverter"/>
<!--[if gte mso 9]><xml>
 <o:DocumentProperties>
  <o:Author>Баранько Александр В</o:Author>
  <o:Template>Normal</o:Template>
  <o:LastAuthor>bravada</o:LastAuthor>
  <o:Revision>2</o:Revision>
  <o:TotalTime>1</o:TotalTime>
  <o:Created>2020-04-20T19:01:00Z</o:Created>
  <o:LastSaved>2020-04-20T19:01:00Z</o:LastSaved>
  <o:Pages>1</o:Pages>
  <o:Words>2162</o:Words>
  <o:Characters>12327</o:Characters>
  <o:Lines>102</o:Lines>
  <o:Paragraphs>28</o:Paragraphs>
  <o:CharactersWithSpaces>14461</o:CharactersWithSpaces>
  <o:Version>11.9999</o:Version>
 </o:DocumentProperties>
 <o:OfficeDocumentSettings>
  <o:AllowPNG/>
  <o:TargetScreenSize>1024x768</o:TargetScreenSize>
 </o:OfficeDocumentSettings>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:WordDocument>
  <w:SpellingState>Clean</w:SpellingState>
  <w:GrammarState>Clean</w:GrammarState>
  <w:PunctuationKerning/>
  <w:ValidateAgainstSchemas/>
  <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid>
  <w:IgnoreMixedContent>false</w:IgnoreMixedContent>
  <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText>
  <w:Compatibility>
   <w:BreakWrappedTables/>
   <w:SnapToGridInCell/>
   <w:WrapTextWithPunct/>
   <w:UseAsianBreakRules/>
   <w:DontGrowAutofit/>
  </w:Compatibility>
 </w:WordDocument>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <w:LatentStyles DefLockedState=3D"false" LatentStyleCount=3D"156">
 </w:LatentStyles>
</xml><![endif]--><!--[if !mso]><object
 classid=3D"clsid:38481807-CA0E-42D2-BF39-B33AF135CC4D" id=3Dieooui></objec=
t>
<style>
st1\:*{behavior:url(#ieooui) }
</style>
<![endif]-->
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:PMingLiU;
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-alt:\65B0\7D30\660E\9AD4;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610611969 684719354 22 0 1048577 0;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;
	mso-font-charset:204;
	mso-generic-font-family:swiss;
	mso-font-pitch:variable;
	mso-font-signature:-536870145 1073786111 1 0 415 0;}
@font-face
	{font-family:"\@PMingLiU";
	panose-1:2 2 5 0 0 0 0 0 0 0;
	mso-font-charset:136;
	mso-generic-font-family:roman;
	mso-font-pitch:variable;
	mso-font-signature:-1610611969 684719354 22 0 1048577 0;}
@font-face
	{font-family:TimesET;
	panose-1:0 0 0 0 0 0 0 0 0 0;
	mso-font-alt:"Arial Unicode MS";
	mso-font-charset:0;
	mso-generic-font-family:roman;
	mso-font-format:other;
	mso-font-pitch:auto;
	mso-font-signature:4522099 84 16777216 0 1701669204 542393715;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{mso-style-parent:"";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:8.0pt;
	margin-left:0cm;
	line-height:107%;
	mso-pagination:widow-orphan;
	font-size:11.0pt;
	font-family:Calibri;
	mso-fareast-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:EN-US;}
h1
	{mso-style-link:" Знак Знак3";
	mso-style-next:Обычный;
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:center;
	mso-pagination:widow-orphan;
	page-break-after:avoid;
	mso-outline-level:1;
	font-size:12.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-font-kerning:0pt;
	mso-ansi-language:UK;
	mso-fareast-language:UK;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:" Знак Знак2";
	mso-style-next:Обычный;
	margin-top:12.0pt;
	margin-right:0cm;
	margin-bottom:3.0pt;
	margin-left:0cm;
	mso-pagination:widow-orphan;
	mso-outline-level:7;
	font-size:12.0pt;
	font-family:Calibri;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-AU;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:" Знак Знак1";
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:140%;
	mso-pagination:none;
	font-size:14.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:" Знак Знак";
	margin-top:0cm;
	margin-right:0cm;
	margin-bottom:6.0pt;
	margin-left:0cm;
	line-height:200%;
	mso-pagination:widow-orphan;
	font-size:12.0pt;
	mso-bidi-font-size:11.0pt;
	font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:UK;}
span.3
	{mso-style-name:" Знак Знак3";
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Заголовок 1";
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:UK;
	font-weight:bold;}
span.2
	{mso-style-name:" Знак Знак2";
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Заголовок 7";
	mso-ansi-font-size:12.0pt;
	mso-bidi-font-size:12.0pt;
	font-family:Calibri;
	mso-ascii-font-family:Calibri;
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:Calibri;
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:EN-AU;
	mso-fareast-language:RU;}
span.1
	{mso-style-name:" Знак Знак1";
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Основной текст";
	mso-ansi-font-size:14.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-fareast-language:RU;}
p.10, li.10, div.10
	{mso-style-name:Стан1;
	margin:0cm;
	margin-bottom:.0001pt;
	text-align:justify;
	line-height:120%;
	mso-pagination:none;
	font-size:14.0pt;
	mso-bidi-font-size:10.0pt;
	font-family:TimesET;
	mso-ascii-font-family:TimesET;
	mso-fareast-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";}
span.a
	{mso-style-name:" Знак Знак";
	mso-style-locked:yes;
	mso-style-parent:"";
	mso-style-link:"Основной текст 2";
	mso-ansi-font-size:12.0pt;
	font-family:"Times New Roman";
	mso-ascii-font-family:"Times New Roman";
	mso-fareast-font-family:"Times New Roman";
	mso-hansi-font-family:"Times New Roman";
	mso-bidi-font-family:"Times New Roman";
	mso-ansi-language:UK;
	mso-fareast-language:UK;}
span.30
	{mso-style-name:"Основной текст \(3\)";
	mso-style-parent:"";
	mso-ansi-font-size:7.0pt;
	color:black;
	position:relative;
	top:0pt;
	mso-text-raise:0pt;
	letter-spacing:.3pt;
	mso-font-width:100%;
	mso-ansi-language:UK;
	mso-fareast-language:UK;
	text-decoration:underline;
	text-underline:single;}
span.SpellE
	{mso-style-name:"";
	mso-spl-e:yes;}
span.GramE
	{mso-style-name:"";
	mso-gram-e:yes;}
@page Section1
	{size:595.3pt 841.9pt;
	margin:2.0cm 42.5pt 2.0cm 3.0cm;
	mso-header-margin:35.4pt;
	mso-footer-margin:35.4pt;
	mso-paper-source:0;}
div.Section1
	{page:Section1;}
-->
</style>
<!--[if gte mso 10]>
<style>
 /* Style Definitions */
 table.MsoNormalTable
	{mso-style-name:"Обычная таблица";
	mso-tstyle-rowband-size:0;
	mso-tstyle-colband-size:0;
	mso-style-noshow:yes;
	mso-style-parent:"";
	mso-padding-alt:0cm 5.4pt 0cm 5.4pt;
	mso-para-margin:0cm;
	mso-para-margin-bottom:.0001pt;
	mso-pagination:widow-orphan;
	font-size:10.0pt;
	font-family:Calibri;
	mso-ansi-language:#0400;
	mso-fareast-language:#0400;
	mso-bidi-language:#0400;}
</style>
<![endif]--><!--[if gte mso 9]><xml>
 <o:shapedefaults v:ext=3D"edit" spidmax=3D"2050"/>
</xml><![endif]--><!--[if gte mso 9]><xml>
 <o:shapelayout v:ext=3D"edit">
  <o:idmap v:ext=3D"edit" data=3D"1"/>
 </o:shapelayout></xml><![endif]-->
</head>

<body lang=3DRU style=3D'tab-interval:35.4pt'>

<div class=3DSection1>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-layout-grid-align:none;text-autosp=
ace:
none'><b><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New R=
oman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>ІНСТРУКЦІЯ<o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-layout-grid-align:none;text-autosp=
ace:
none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'>для медичного застосування
лікарського засобу</span></b><b style=3D'mso-bidi-font-weight:normal'><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:RU'><o:p></o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-layout-grid-align:none;text-autosp=
ace:
none'><b style=3D'mso-bidi-font-weight:normal'><span style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-layout-grid-align:none;text-autosp=
ace:
none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>САЛЬБУТАМОЛ-НЕО<o:p></o:p></s=
pan></b></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal;mso-layout-grid-align:none;text-autosp=
ace:
none'><b style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>(SALBUTAMOL-NEO)<o:p></o:p></=
span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><b><span style=3D'font-size:12.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'><o:p>&nb=
sp;</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:UK'>Склад:</span></i></b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:UK'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>діюча речов=
ина:<b
style=3D'mso-bidi-font-weight:normal'> </b></span></i><span class=3DSpellE>=
<span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>сальбутамол=
у</span></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> сульфат;<o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>1 доза аерозолю містить<b style=3D'mso-bidi-fon=
t-weight:
normal'> </b>100</span><span lang=3DUK style=3D'font-size:12.0pt;font-famil=
y:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'> </span>=
<span
class=3DSpellE><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times=
 New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>мкг</span></span><span lang=3DUK style=3D'font-size:12.0pt;font-family:=
"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'> <span class=3DSpellE>сальбутамолу</span> сульфату (у перерахуванні на =
<span
class=3DSpellE>сальбутамол</span>); <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>допоміжні речовини: </span></=
i><span
class=3DSpellE><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times=
 New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>олеїловий</span></span><span lang=3DUK style=3D'font-size:12.0pt;font-f=
amily:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'> спирт, етанол</span><span style=3D'font-size:1=
2.0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-fareast-language:RU'> 96&nbsp;%</span><span lang=3DUK style=3D'font-siz=
e:12.0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>, </span><span class=3DSpellE=
><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:RU'>тетрафторетан</span></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>.</span><sp=
an
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:RU'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span style=3D'font-size:12.0pt;font-family:"Ti=
mes New Roman";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:467.75pt'><b style=3D'mso-bidi-font-we=
ight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK;mso-bidi-font-style:italic'>Лікарська форма. </span></b><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Інгаляція п=
ід
тиском, 100 <span class=3DSpellE>мкг</span>/доза.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:467.75pt'><i style=3D'mso-bidi-font-st=
yle:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Основні фізико-хімічні властивості:</span></i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> біла або м=
айже
біла суспензія, що знаходиться під тиском у контейнері (балоні алюмінієвому=
 з
клапаном дозуючої дії), обладнаному насадкою-інгалятором із захисним ковпач=
ком;
препарат при виході з балона розпилюється у вигляді аерозольного струменя.<=
o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-layout-grid-align:none;text-autospace:none'>=
<span
class=3DSpellE><b style=3D'mso-bidi-font-weight:normal'><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK;mso-bidi-fon=
t-style:
italic'>Фармакотерапевтична</span></b></span><b style=3D'mso-bidi-font-weig=
ht:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK;mso-bidi-font-style:italic'> група. </span></b><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Засоби, що
застосовуються при обструктивних захворюваннях дихальних шляхів. <span
class=3DSpellE>Протиастматичні</span> препарати. Адренергічні препарати для
інгаляційного застосування. Селективні агоністи бета-2-адренорецепторів. <s=
pan
class=3DSpellE>Сальбутамол</span>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Код АТХ R03A C02.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><b style=3D'mso-bidi-font-w=
eight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'>Фармакологічні властивості.<o=
:p></o:p></span></i></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><span class=3DSpellE><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>Фармакодинаміка</span></i></s=
pan><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>. <o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><span class=3DSpellE><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>Сальбутамол=
-Нео</span></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'> є селектив=
ним
агоністом бета 2-адренорецепторів. У терапевтичних дозах діє на
бета-2-адренорецептори гладкої мускулатури бронхів, забезпечуючи швидку
(протягом 5 хвилин) та короткотривалу (4</span><span lang=3DUK style=3D'fon=
t-size:
14.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-fareast-=
font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>–</span><sp=
an
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>6 годин) <s=
pan
class=3DSpellE>бронходилатацію</span> у хворих з оборотною обструкцією диха=
льних
шляхів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><i style=3D'mso-bidi-font-s=
tyle:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Фармакокінетика.</span></i><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'> <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'>При інгаляції лікарського зас=
обу
10</span><span lang=3DUK style=3D'font-size:14.0pt;mso-bidi-font-size:10.0p=
t;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>–</span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>20&nbsp;% в=
веденої
дози досягають нижніх дихальних шляхів. </span><span class=3DSpellE><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:RU'>Решта</span></span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:RU'> <span class=3DSpellE>дози</span=
> <span
class=3DSpellE>залишається</span> у «<span class=3DSpellE>доставляючій</spa=
n>»<sup>
</sup><span class=3DSpellE>системі</span> <span class=3DSpellE>або</span> у=
 <span
class=3DSpellE>носоглотці</span>, <span class=3DSpellE>звідки</span> <span
class=3DSpellE>всмоктується</span>. <span class=3DSpellE>Частина</span> <sp=
an
class=3DSpellE>дози</span>, <span class=3DSpellE>що</span> <span class=3DSp=
ellE>досягла</span>
<span class=3DSpellE>дихальних</span> <span class=3DSpellE>шляхів</span>, <=
span
class=3DSpellE>абсорбується</span> у <span class=3DSpellE>тканині</span> <s=
pan
class=3DSpellE>легені<span class=3DGramE>в</span></span> та <span class=3DS=
pellE>потрапляє</span>
у <span class=3DSpellE>кровообіг</span>, але не <span class=3DSpellE>метабо=
лізується</span>
</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Rom=
an";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>у</span><span style=3D'font-size:12.0pt;font-family:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'> <span
class=3DSpellE>легенях</span>. <span class=3DSpellE><span class=3DGramE>П</=
span>ісля</span>
<span class=3DSpellE>потрапляння</span> у <span class=3DSpellE>системний</s=
pan> <span
class=3DSpellE>кровообіг</span> препарат <span class=3DSpellE>метаболізуєть=
ся</span>
у <span class=3DSpellE>печінці</span> та <span class=3DSpellE>виділяється</=
span>, <span
class=3DSpellE>головним</span> чином, <span class=3DSpellE>нирками</span> у=
 <span
class=3DSpellE>незміненому</span> <span class=3DSpellE>вигляді</span> та у =
<span
class=3DSpellE>вигляді</span> неактивного <span class=3DSpellE>фенолсульфат=
ного</span>
<span class=3DSpellE>метаболіту</span>. <span class=3DSpellE>Частина</span>=
 <span
class=3DSpellE>дози</span> препарату, <span class=3DSpellE>що</span> з носо=
глотки <span
class=3DSpellE>потрапила</span> до <span class=3DSpellE>травної</span> <span
class=3DSpellE>системи</span>, <span class=3DSpellE>всмоктується</span> <sp=
an
class=3DSpellE>зі</span> <span class=3DSpellE>шлунково-кишкового</span> тра=
кту,
проходить перший <span class=3DSpellE>етап</span> <span class=3DSpellE>мета=
болізму</span>
в <span class=3DSpellE>печінці</span> до <span class=3DSpellE>фенолсульфатн=
ої</span>
<span class=3DSpellE>сполуки</span>, а <span class=3DSpellE>поті<span class=
=3DGramE>м</span></span>
<span class=3DSpellE>виділяється</span> <span class=3DSpellE>нирками</span>=
.</span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'> </span><sp=
an
class=3DSpellE><span class=3DGramE><span style=3D'font-size:12.0pt;font-fam=
ily:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>Б</span>=
</span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:RU'>ільша</span></span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:RU'> <span class=3DSpellE>частина</s=
pan>
препарату <span class=3DSpellE>виводиться</span> <span class=3DSpellE>із</s=
pan> <span
class=3DSpellE>організму</span> <span class=3DSpellE>протягом</span> 72 год=
ин. <span
class=3DSpellE>Зв’язування</span> з <span class=3DSpellE>білками</span> <sp=
an
class=3DSpellE>плазми</span> </span><span lang=3DUK style=3D'font-size:12.0=
pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>крові </span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:RU'>становить 10&nbsp;%.</span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><b style=3D'mso-bidi-font-w=
eight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Клінічні характеристики.<o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><b style=3D'mso-bidi-font-w=
eight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'>Показання.</span></i></b><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Короткотривале (від 4 до 6 годин) розширення
бронхів зі швидким початком (приблизно протягом 5 хвилин) при обструкції
дихальних шляхів.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span class=3DSpellE><span lang=3DUK style=3D'f=
ont-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Купірування</span></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> нападів яд=
ухи
при захворюваннях, що супроводжуються обструкцією дихальних шляхів, таких як
бронхіальна астма.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Профілактика приступів <span class=3DSpellE>бро=
нхоспазму</span>,
пов’язаних з дією алергену або спричинених фізичним навантаженням.<o:p></o:=
p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>У комплексній терапії хворих на бронхіальну аст=
му. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:UK'>Протипоказання. </span></i></=
b><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Гіперчутлив=
ість
в анамнезі до будь-якого компонента лікарського засобу. Хоча <span
class=3DSpellE>сальбутамол</span> у формі розчину для внутрішньовенних ін’є=
кцій
та інколи у формі таблеток застосовується при передчасних пологах, <span
class=3DSpellE>сальбутамол</span> у формі аерозолю для інгаляцій при цих
показаннях не застосовується. Не застосовують <span class=3DSpellE>сальбута=
мол</span>
у разі загрози аборту.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:467.75pt'><b style=3D'mso-bidi-font-we=
ight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Взаємодія з іншими лікарськими
засобами та інші види взаємодій</span></i></b><b style=3D'mso-bidi-font-wei=
ght:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>.</span></b><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Time=
s New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'> <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:467.75pt'><span class=3DSpellE><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Сальбутамол=
</span></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> не слід
призначати разом з такими неселективними <span class=3DSpellE>бета-адренобл=
окаторами</span>,
як <span class=3DSpellE>пропранолол</span>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:467.75pt'><span class=3DSpellE><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Сальбутамол=
</span></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> не
протипоказаний для призначення хворим, які</span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:UK'> </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>лікуються
інгібіторами <span class=3DSpellE>моноаміноксидази</span> (МАО).<o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><b style=3D'mso-bidi-font-w=
eight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'>Особливості застосування</spa=
n></i></b><b
style=3D'mso-bidi-font-weight:normal'><span lang=3DUK style=3D'font-size:12=
.0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>. <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'>Щоб упевнитися в оптимальному
потраплянні лікарського засобу у легені хворого, слід перевірити його техні=
ку
проведення інгаляції. Пацієнтів слід попередити, що вони можуть відчувати і=
нший
смак порівняно з таким при використанні попереднього інгалятора.<o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Раптове та прогресуюче погіршення перебігу
бронхіальної астми є життєво небезпечним станом, що потребує початку лікува=
ння
або збільшення застосовуваної дози кортикостероїдів. Пацієнтам, які належат=
ь до
групи ризику, рекомендується щоденно проводити контроль максимальної швидко=
сті
видиху.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span class=3DSpellE><span lang=3DUK style=3D'f=
ont-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'>Бронходилатаційні</span></spa=
n><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'> препарати =
не
повинні бути єдиними або головними препаратами у лікуванні хворих на тяжку =
або
нестабільну бронхіальну астму. Стан таких хворих необхідно регулярно
контролювати, у т. ч. проводити легеневі тести, оскільки тяжка бронхіальна
астма є життєво небезпечним захворюванням, і може потребуватися призначення
інгаляційних та/або пероральних <span class=3DSpellE>глюкокортикостероїдів<=
/span>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>Якщо дія звичайної дози <span class=3DSpellE>са=
льбутамолу</span>
стає менш ефективною або зменшується тривалість її дії (менше 3 годин),
пацієнту слід звернутися до лікаря. Збільшення дози або частоти застосування
препарату призначає лише лікар.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>Збільшення потреби у застосуванні <span
class=3DSpellE>бронходилататорів</span>, особливо короткодіючих інгаляційних
бета-2-агоністів, для контролю симптомів бронхіальної астми свідчить про
загострення захворювання. У цих випадках слід переглянути план лікування та
вирішити питання про призначення більших доз інгаляційних кортикостероїдів =
або
курсу пероральних кортикостероїдів. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>Тяжке загострення бронхіальної астми слід лікув=
ати
у звичайному режимі.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span class=3DSpellE><span lang=3DUK style=3D'f=
ont-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Симпатоміметики</span></span>=
<span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>, включаючи=
 <span
class=3DSpellE>сальбутамол</span>, впливають на серцево-судинну систему. За
даними <span class=3DSpellE>післяреєстраційного</span> застосування та дани=
ми
наукових публікацій, відомо про рідкі випадки виникнення ішемії міокарда,
асоційованої із застосуванням <span class=3DSpellE>сальбутамолу</span>.
Пацієнтам, які мають хвороби серця (наприклад, ішемічну хворобу серця, арит=
мію
або тяжку серцеву недостатність) та лікуються <span class=3DSpellE>сальбута=
молом</span>,
у разі виникнення у них болю у грудях або інших симптомів, що свідчать про
загострення серцевої хвороби, слід звернутися за медичною допомогою. Слід
звернути увагу на оцінку таких симптомів, як задишка та біль у грудях, що
можуть бути наслідком як хвороби серця, так і захворювань дихальної системи=
. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>З обережністю <span class=3DSpellE>сальбутамол<=
/span>
потрібно призначати хворим на тиреотоксикоз.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Результатом лікування бета-2-агоністами може бу=
ти
тяжка <span class=3DSpellE>гіпокаліємія</span>; головним чином це спостеріг=
ається
при застосуванні парентеральних форм або <span class=3DSpellE>небулайзера</=
span>.
Особливу увагу приділяють хворим на гостру тяжку бронхіальну астму, тому що=
 <span
class=3DSpellE>гіпокаліємія</span> може <span class=3DSpellE>потенціюватися=
</span>
супутнім застосуванням дериватів <span class=3DSpellE>ксантинів</span>,
стероїдів, <span class=3DSpellE>діуретиків</span> і гіпоксією. У цій ситуац=
ії
рекомендується перевіряти рівень калію у сироватці крові.<o:p></o:p></span>=
</p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span class=3DSpellE><span lang=3DUK style=3D'f=
ont-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Сальбутамол</span></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> з обережні=
стю
застосовують для лікування хворих, які отримують великі дози інших <span
class=3DSpellE>симпатоміметиків</span>. Як і інші агоністи <span class=3DSp=
ellE>бета-адренорецепторів</span>,
<span class=3DSpellE>сальбутамол</span> може призводити до зворотних метабо=
лічних
змін, наприклад до збільшення рівня цукру крові. Компенсація таких змін у
хворих на цукровий діабет не завжди можлива, тому є окремі повідомлення про
розвиток <span class=3DSpellE>кетоацидозу</span> у таких хворих. Одночасне
застосування кортикостероїдів може загострити цей стан.<o:p></o:p></span></=
p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Як і при застосуванні інших інгаляційних
препаратів, можливий парадоксальний <span class=3DSpellE>бронхоспазм</span>=
 з
негайним посиленням задишки після застосування препарату. У цьому випадку
необхідно одразу призначати альтернативні форми препарату або інші швидкоді=
ючі
інгаляційні <span class=3DSpellE>бронходилататори</span>. <span class=3DSpe=
llE>Сальбутамол</span>
слід негайно відмінити, провести оцінку стану пацієнта і у разі необхідності
призначити інший швидкодіючий <span class=3DSpellE>бронходилататор</span> на
постійній основі.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span class=3DSpellE><i style=3D'mso-bidi-font-=
style:
normal'><span style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-f=
areast-font-family:
"Times New Roman";mso-fareast-language:RU'>Застосування</span></i></span><i
style=3D'mso-bidi-font-style:normal'><span style=3D'font-size:12.0pt;font-f=
amily:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-fareast-lan=
guage:
RU'> </span></i><span class=3DGramE><i style=3D'mso-bidi-font-style:normal'=
><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>у</span></i=
><i
style=3D'mso-bidi-font-style:normal'><span style=3D'font-size:12.0pt;font-f=
amily:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-fareast-lan=
guage:
RU'> <span class=3DSpellE>пер</span></span></i></span><span class=3DSpellE>=
<i
style=3D'mso-bidi-font-style:normal'><span style=3D'font-size:12.0pt;font-f=
amily:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-fareast-lan=
guage:
RU'>іод</span></i></span><i style=3D'mso-bidi-font-style:normal'><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:RU'> <span class=3DSpellE>вагітності=
</span>
<span class=3DSpellE>або</span> <span class=3DSpellE>годування</span> <span
class=3DSpellE>груддю</span>.</span></i><span style=3D'font-size:12.0pt;fon=
t-family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-fareast-lan=
guage:
RU'> <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>За даними досліджень на тваринах, <span
class=3DSpellE>сальбутамол</span> має репродуктивну токсичність. Безпека
застосування вагітним не встановлена. Контрольованих клінічних досліджень щ=
одо
застосування <span class=3DSpellE>сальбутамолу</span> вагітним не проводило=
ся.
Були поодинокі повідомлення про різні вроджені вади при внутрішньоутробному=
 розвитку,
включаючи розщілину піднебіння, дефекти кінцівок та серцеві порушення (деякі
жінки у період вагітності приймали багато інших лікарських засобів). <span
class=3DSpellE>Сальбутамол</span> не слід приймати у період вагітності</spa=
n><span
style=3D'font-size:12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New =
Roman";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>–</span>=
<span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>застосування
можливе лише у разі нагальної потреби. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span class=3DSpellE><span lang=3DUK style=3D'f=
ont-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Сальбутамол</span></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>, вірогідно,
проникає у грудне молоко, тому призначати його жінкам, які годують груддю, =
слід
з обережністю. Чи спричиняє наявність <span class=3DSpellE>сальбутамолу</sp=
an> у
грудному молоці шкідливий вплив на новонародженого<b style=3D'mso-bidi-font=
-weight:
normal'>/</b>немовля, невідомо, тому його застосування жінкам, які годують
груддю, потрібно обмежити випадками, коли користь його застосування для жін=
ки
буде переважати можливий ризик для дитини.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Здатність
впливати на швидкість реакції при керуванні автотранспортом або іншими
механізмами.<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Даних щодо впливу немає. У разі появи побічних
реакцій з боку нервової системи (тремор) керування автотранспортом або робо=
ту з
іншими механізмами необхідно обмежити.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;line-=
height:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:UK'>Спосіб застосування та дози</=
span></i></b><b
style=3D'mso-bidi-font-weight:normal'><i style=3D'mso-bidi-font-style:norma=
l'><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:UK'>.</span></i></b><i style=3D'mso-=
bidi-font-style:
normal'><span style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-f=
areast-font-family:
"Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span class=3DSpellE><span style=3D'font-size:1=
2.0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-fareast-language:RU'>Сальбутамол</span></span><span style=3D'font-size:=
12.0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'> </span><span style=3D'font-s=
ize:
12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-fareast-=
font-family:
"Times New Roman";mso-fareast-language:RU'>–</span><span style=3D'font-size=
:12.0pt;
mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'> </span><sp=
an
class=3DSpellE><span style=3D'font-size:12.0pt;font-family:"Times New Roman=
";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'>аерозоль=
</span></span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:RU'>, <span class=3DSpellE>що</span>=
 <span
class=3DSpellE>призначений</span> <span class=3DSpellE>лише</span> для <span
class=3DSpellE>інгаляційного</span> <span class=3DSpellE>застосування</span=
> через
рот. <span class=3DSpellE>Пацієнтам</span>, <span class=3DSpellE>яким</span=
> тяжко <span
class=3DSpellE>синхронізувати</span> <span class=3DSpellE>дихання</span> <s=
pan
class=3DSpellE>із</span> <span class=3DSpellE>застосуванням</span> <span
class=3DSpellE>інгалятора</span>, <span class=3DSpellE>рекомендується</span=
> <span
class=3DSpellE>додатково</span> <span class=3DSpellE>використовувати</span>=
 <span
class=3DSpellE>спейсер</span></span><span style=3D'font-size:12.0pt;font-fa=
mily:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'> </span><span style=3D'font-size:12.0pt;mso-bid=
i-font-size:
10.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-fareast-language:RU'>–</span><span style=3D'font-size:12.0pt;mso-bidi-f=
ont-size:
10.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'> </span><span class=3DSpellE>=
<span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:RU'>пристрій</span></span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:RU'> для <span class=3DSpellE>полегш=
ення</span>
<span class=3DSpellE>вдихання</span> <span class=3DSpellE>інгаляційних</spa=
n> <span
class=3DSpellE>препараті<span class=3DGramE>в</span></span>.<o:p></o:p></sp=
an></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><u><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>Дорослі </span></u><u><span
lang=3DUK style=3D'font-size:7.0pt;mso-bidi-font-size:12.0pt;font-family:"T=
imes New Roman";
mso-fareast-font-family:"Times New Roman";letter-spacing:.3pt;mso-ansi-lang=
uage:
UK;mso-fareast-language:UK'>(включаючи літніх пацієнтів)</span></u><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>Для <span class=3DSpellE>купірування</span>
загострення симптомів бронхіальної астми, включаючи гострий <span class=3DS=
pellE>бронхоспазм</span>,
можна застосовувати 1 інгаляцію (100 <span class=3DSpellE>мкг</span>) як
мінімальну стартову дозу. У разі необхідності дозу можна збільшити до 200 <=
span
class=3DSpellE>мкг</span> (2 інгаляції). <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>Профілактично за 10</span><span style=3D'font-s=
ize:
12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-fareast-=
font-family:
"Times New Roman";mso-fareast-language:RU'>–</span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>15 хвилин до
фізичного навантаження або очікуваного контакту з алергенами застосовують 2=
00 <span
class=3DSpellE>мкг</span> (2 інгаляції). <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>При тривалій підтримуючій терапії рекомендується
застосовувати 200 <span class=3DSpellE>мкг</span> (2 інгаляції) 4 рази на д=
обу.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><u><span lang=3DUK style=3D'font-size:12.0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>Діти віком від 4 до 12 років<=
/span></u><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'><o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>Для <span class=3DSpellE>купірування</span> гос=
трого <span
class=3DSpellE>бронхоспазму</span> застосовують 1 інгаляцію (100 <span
class=3DSpellE>мкг</span>). У разі необхідності дозу можна збільшити до 200=
 <span
class=3DSpellE>мкг</span> (2 інгаляції).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>Дітям віком від 12 років застосовують дози як д=
ля
дорослих.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>Профілактично за 10</span><span style=3D'font-s=
ize:
12.0pt;mso-bidi-font-size:10.0pt;font-family:"Times New Roman";mso-fareast-=
font-family:
"Times New Roman";mso-fareast-language:RU'>–</span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'>15 хвилин до
фізичного навантаження або очікуваного контакту з алергенами застосовують 2=
00 <span
class=3DSpellE>мкг</span> (2 інгаляції).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>При тривалій підтримуючій терапії рекомендується
застосовувати 200 <span class=3DSpellE>мкг</span> (2 інгаляції) 4 рази на д=
обу.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>Загальна добова доза <span class=3DSpellE>сальб=
утамолу</span>
не повинна перевищувати 800 <span class=3DSpellE>мкг</span> (8 інгаляцій).
Підвищена потреба у бета-2-агоністах може свідчити про погіршення перебігу
бронхіальної астми. За цих умов слід переглянути режим лікування пацієнта та
розглянути необхідність призначення <span class=3DSpellE>глюкокортикостерої=
дної</span>
терапії.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:163.1pt'><i style=3D'mso-bidi-font-sty=
le:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'><o:p>&nbsp;</o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:163.1pt'><i style=3D'mso-bidi-font-sty=
le:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Підготовка до першого використання.</span></i><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'><o:p></o:p>=
</span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Перед першим використанням контейнера слід зняти
захисний ковпачок з насадки-інгалятора. Потім добре струснути контейнер
вертикальними рухами, перевернути контейнер насадкою-інгалятором донизу та
зробити два розпилення у повітря, щоб переконатися в адекватній роботі. У р=
азі
перерви в користуванні протягом кількох днів слід зробити одне розпилення у
повітря після ретельного струшування контейнера.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Користуванн=
я</span></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>:<o:p></o:p=
></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>1. Зняти захисний ковпачок з насадки-інгалятора.
Переконатися в чистоті внутрішньої і зовнішньої поверхонь насадки-інгалятор=
а.</span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal'><span lang=3DUK style=3D'font-size:12=
.0pt;
font-family:"Times New Roman";mso-fareast-font-family:PMingLiU;mso-ansi-lan=
guage:
UK;mso-no-proof:yes'><!--[if gte vml 1]><v:shapetype id=3D"_x0000_t75"
 coordsize=3D"21600,21600" o:spt=3D"75" o:preferrelative=3D"t" path=3D"m@4@=
5l@4@11@9@11@9@5xe"
 filled=3D"f" stroked=3D"f">
 <v:stroke joinstyle=3D"miter"/>
 <v:formulas>
  <v:f eqn=3D"if lineDrawn pixelLineWidth 0"/>
  <v:f eqn=3D"sum @0 1 0"/>
  <v:f eqn=3D"sum 0 0 @1"/>
  <v:f eqn=3D"prod @2 1 2"/>
  <v:f eqn=3D"prod @3 21600 pixelWidth"/>
  <v:f eqn=3D"prod @3 21600 pixelHeight"/>
  <v:f eqn=3D"sum @0 0 1"/>
  <v:f eqn=3D"prod @6 1 2"/>
  <v:f eqn=3D"prod @7 21600 pixelWidth"/>
  <v:f eqn=3D"sum @8 21600 0"/>
  <v:f eqn=3D"prod @7 21600 pixelHeight"/>
  <v:f eqn=3D"sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok=3D"f" gradientshapeok=3D"t" o:connecttype=3D"rect"/>
 <o:lock v:ext=3D"edit" aspectratio=3D"t"/>
</v:shapetype><v:shape id=3D"Рисунок_x0020_3" o:spid=3D"_x0000_i1025" type=
=3D"#_x0000_t75"
 style=3D'width:116.25pt;height:88.5pt;visibility:visible'>
 <v:imagedata src=3D"UA105300101_E2BF.files/image001.emz" o:title=3D""/>
</v:shape><![endif]--><![if !vml]><img width=3D155 height=3D118
src=3D"UA105300101_E2BF.files/image002.png" v:shapes=3D"Рисунок_x0020_3"><!=
[endif]></span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>2. Добре струснути контейнер вертикальними руха=
ми.</span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal'><span lang=3DEN-US style=3D'font-size=
:12.0pt;
font-family:"Times New Roman";mso-fareast-font-family:PMingLiU;mso-ansi-lan=
guage:
EN-US;mso-no-proof:yes'><!--[if gte vml 1]><v:shape id=3D"Рисунок_x0020_2"
 o:spid=3D"_x0000_i1026" type=3D"#_x0000_t75" style=3D'width:95.25pt;height=
:84pt;
 visibility:visible'>
 <v:imagedata src=3D"UA105300101_E2BF.files/image003.emz" o:title=3D""/>
</v:shape><![endif]--><![if !vml]><img width=3D127 height=3D112
src=3D"UA105300101_E2BF.files/image004.png" v:shapes=3D"Рисунок_x0020_2"><!=
[endif]></span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>3. Перевернути контейнер насадкою-інгалятором
донизу, тримати контейнер вертикально між великим пальцем та середнім і
вказівним пальцями так, щоб великий палець знаходився під насадкою-інгалято=
ром.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>4. Зробити максимально глибокий видих, потім
помістити насадку-інгалятор у рот між зубами і охопити її губами, не прикуш=
уючи
при цьому.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>5. Починаючи вдих через рот, натиснути на верхі=
вку
контейнера, щоб зробити розпилення препарату, при цьому продовжувати повіль=
но і
глибоко вдихати.</span><span style=3D'font-size:12.0pt;font-family:"Times N=
ew Roman";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'><o:p></o=
:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>6. Затримати дихання, вийняти насадку-інгалятор=
 з
рота і зняти палець з верхівки контейнера. Продовжувати затримувати дихання
стільки, скільки можливо.</span><span style=3D'font-size:12.0pt;font-family=
:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'><o:p></o=
:p></span></p>

<p class=3DMsoNormal align=3Dcenter style=3D'margin-bottom:0cm;margin-botto=
m:.0001pt;
text-align:center;line-height:normal'><span lang=3DUK style=3D'font-size:12=
.0pt;
font-family:"Times New Roman";mso-fareast-font-family:PMingLiU;mso-ansi-lan=
guage:
UK;mso-no-proof:yes'><!--[if gte vml 1]><v:shape id=3D"Рисунок_x0020_1" o:s=
pid=3D"_x0000_i1027"
 type=3D"#_x0000_t75" style=3D'width:93pt;height:77.25pt;visibility:visible=
'>
 <v:imagedata src=3D"UA105300101_E2BF.files/image005.emz" o:title=3D""/>
</v:shape><![endif]--><![if !vml]><img width=3D124 height=3D103
src=3D"UA105300101_E2BF.files/image006.png" v:shapes=3D"Рисунок_x0020_1"><!=
[endif]></span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>7. Якщо необхідно виконати наступну інгаляцію, =
слід
зачекати приблизно 30 секунд, тримаючи інгалятор вертикально, після цього
виконати пункти 2</span><span lang=3DUK style=3D'font-size:12.0pt;mso-bidi-=
font-size:
11.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>–</span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>6.<o:p></o:=
p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Закрити насадку-інгалятор захисним ковпачком.<o=
:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>ВАЖЛИВО:<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Виконувати пункти 4, 5 та 6 не поспішаючи. Важл=
иво
перед самим розпиленням почати вдихати якомога повільніше. Перші кілька раз=
ів
слід потренуватися перед дзеркалом. Якщо з боків рота з’явиться «хмарка»,
необхідно почати знову з пункту 2.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><i style=3D'mso-bidi-font-style:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Чистка</spa=
n></i><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>:<i
style=3D'mso-bidi-font-style:normal'><o:p></o:p></i></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Насадку-інгалятор слід чистити не рідше 1 разу =
на
тиждень.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>1. Зняти захисний ковпачок з насадки-інгалятора=
, а
насадку-інгалятор зняти з контейнера.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:467.75pt'><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>2. Ретельно вимити насадку-ін=
галятор
і захисний ковпачок під теплою проточною водою.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:467.75pt'><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>3. Ретельно висушити
насадку-інгалятор і захисний ковпачок зсередини та ззовні.<o:p></o:p></span=
></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:467.75pt'><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>4. Надіти насадку-інгалятор на
контейнер та шток клапана, закрити вільний отвір насадки-інгалятора захисним
ковпачком.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;tab-stops:467.75pt'><span lang=3DUK style=3D'fon=
t-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Не зануряти контейнер у воду!=
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><i style=3D'mso-bidi-font-s=
tyle:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Діти.<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'>Застосовують дітям віком від 4
років.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>Передозування.</span></i></b>=
<span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:RU'> <o:p></o:p=
></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>Найбільш поширеними ознаками та симптомами
передозування <span class=3DSpellE>сальбутамолу</span> є <span class=3DSpel=
lE>транзиторні</span>
зміни, <span class=3DSpellE>фармакологічно</span> індуковані бета-агоністам=
и,
наприклад тахікардія, тремор, гіперактивність та метаболічні порушення,
включаючи <span class=3DSpellE>гіпокаліємію</span> (див. розділ «Особливості
застосування» та «Побічні реакції»).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:RU'>У результаті передозування <span class=3DSpellE=
>сальбутамолом</span>
може виникнути <span class=3DSpellE>гіпокаліємія</span>, тому необхідно
перевіряти рівень калію у сироватці крові. При застосуванні високих
терапевтичних доз або передозуванні короткодіючих бета-агоністів повідомлял=
ося
про випадки <span class=3DSpellE>лактоацидозу</span>. Тому слід перевіряти =
рівень
лактату в сироватці крові та відповідно контролювати метаболічний ацидоз,
особливо у разі стійкого або наростаючого прискореного дихання незважаючи на
покращання симптомів <span class=3DSpellE>бронхоспазму</span>, таких як <sp=
an
class=3DSpellE>стридорозне</span> дихання.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><b style=3D'mso-bidi-font-w=
eight:
normal'><i style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Побічні реакції. </span></i><=
/b><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Побічні
реакції, наведені нижче, класифіковані за органами і системами, а також за
частотою їх виникнення: дуже часто (</span><span lang=3DUK style=3D'font-si=
ze:12.0pt;
font-family:Symbol;mso-ascii-font-family:"Times New Roman";mso-fareast-font=
-family:
"Times New Roman";mso-hansi-font-family:"Times New Roman";mso-ansi-language:
UK;mso-fareast-language:UK;mso-char-type:symbol;mso-symbol-font-family:Symb=
ol'><span
style=3D'mso-char-type:symbol;mso-symbol-font-family:Symbol'>&sup3;</span><=
/span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> 1/10), час=
то (</span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:Symbol;mso-ascii-font-famil=
y:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:"Times New =
Roman";
mso-ansi-language:UK;mso-fareast-language:UK;mso-char-type:symbol;mso-symbo=
l-font-family:
Symbol'><span style=3D'mso-char-type:symbol;mso-symbol-font-family:Symbol'>=
&sup3;</span></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> 1/100 та <=
/span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:Symbol;mso-ascii-font-famil=
y:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:"Times New =
Roman";
mso-ansi-language:UK;mso-fareast-language:UK;mso-char-type:symbol;mso-symbo=
l-font-family:
Symbol'><span style=3D'mso-char-type:symbol;mso-symbol-font-family:Symbol'>=
&lt;</span></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> 1/10), неч=
асто
(</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:Symbol;mso-as=
cii-font-family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-hansi-font-=
family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK;mso-char-typ=
e:
symbol;mso-symbol-font-family:Symbol'><span style=3D'mso-char-type:symbol;
mso-symbol-font-family:Symbol'>&sup3;</span></span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> 1/1000 та =
</span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:Symbol;mso-ascii-font-famil=
y:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:"Times New =
Roman";
mso-ansi-language:UK;mso-fareast-language:UK;mso-char-type:symbol;mso-symbo=
l-font-family:
Symbol'><span style=3D'mso-char-type:symbol;mso-symbol-font-family:Symbol'>=
&lt;</span></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> 1/100), рі=
дко
(</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:Symbol;mso-as=
cii-font-family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-hansi-font-=
family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK;mso-char-typ=
e:
symbol;mso-symbol-font-family:Symbol'><span style=3D'mso-char-type:symbol;
mso-symbol-font-family:Symbol'>&sup3;</span></span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> 1/10000 та=
 </span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:Symbol;mso-ascii-font-famil=
y:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-hansi-font-family:"Times New =
Roman";
mso-ansi-language:UK;mso-fareast-language:UK;mso-char-type:symbol;mso-symbo=
l-font-family:
Symbol'><span style=3D'mso-char-type:symbol;mso-symbol-font-family:Symbol'>=
&lt;</span></span><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> 1/1000), д=
уже
рідко (</span><span lang=3DUK style=3D'font-size:12.0pt;font-family:Symbol;
mso-ascii-font-family:"Times New Roman";mso-fareast-font-family:"Times New =
Roman";
mso-hansi-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-la=
nguage:
UK;mso-char-type:symbol;mso-symbol-font-family:Symbol'><span style=3D'mso-c=
har-type:
symbol;mso-symbol-font-family:Symbol'>&lt;</span></span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> 1/10000),
включаючи поодинокі випадки, частота невідома. <o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:7'><i style=3D'mso-bidi-font-s=
tyle:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>З боку імунної<span style=3D'mso-spacerun:yes'>  </span>системи<o:p></o=
:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Дуже рідко: реакції <span
class=3DSpellE>гіперчутливості</span>, включаючи <span class=3DSpellE>ангіо=
невротичний</span>
набряк, кропив’янку, <span class=3DSpellE>бронхоспазм</span>, артеріальну <=
span
class=3DSpellE>гіпотензію</span> та колапс.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:7'><i style=3D'mso-bidi-font-s=
tyle:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>З боку обміну речовин, метаболізму<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Рідко: <span class=3DSpellE>г=
іпокаліємія</span>.
Потенційно застосування бета-2-агоністів може зумовити виражену <span
class=3DSpellE>гіпокаліємію</span>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:7'><i style=3D'mso-bidi-font-s=
tyle:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Неврологічні розлади<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'>Часто: тремор, головний біль.=
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Дуже рідко: гіперактивність.<=
o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:7'><span class=3DSpellE><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'>Кардіальні</span></i></span><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:RU'> порушення<o:p></o:p></span><=
/i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Часто: тахікардія.</span><span
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-fareast-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Нечасто: посилене серцебиття.=
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Дуже рідко: порушення серцево=
го
ритму, включаючи фібриляцію передсердь, <span class=3DSpellE>суправентрикул=
ярну</span>
тахікардію та екстрасистолію.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Частота невідома: ішемія міок=
арда
(див. розділ «Особливості застосування»).<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:7'><i style=3D'mso-bidi-font-s=
tyle:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Судинні розлади<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Рідко: периферична <span
class=3DSpellE>вазодилатація</span>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:7'><i style=3D'mso-bidi-font-s=
tyle:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>З боку дихальної системи, органів грудної клітки та середостіння<o:p></=
o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Дуже рідко: парадоксальний <span class=3DSpellE=
>бронхоспазм</span>.
<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:7'><i style=3D'mso-bidi-font-s=
tyle:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Шлунково-кишкові розлади<o:p></o:p></span></i></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Нечасто: подразнення слизових оболонок ротової
порожнини та глотки.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><i style=3D'mso-bidi-font-s=
tyle:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>З боку опорно-рухової системи та сполучної тканини<o:p></o:p></span></i=
></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-outline-level:1'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:UK'>Нечасто: м’язові судоми.<o:p>=
</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><i
style=3D'mso-bidi-font-style:normal'><span lang=3DUK style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-ansi-language:UK;mso-fareast-language:UK'>Термін придатності. </span></=
i></b><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>2 роки. <o:=
p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>Не застосовувати після закінчення терміну
придатності, зазначеного на упаковці.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'><o:p>&nbsp;=
</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Умови
зберігання. </span></b><span lang=3DUK style=3D'font-size:12.0pt;font-famil=
y:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>Зберігати при температурі не вище 25</span><span style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-fareast-language:UK'>&nbsp;</span><span class=3DSpellE><sup><span lang=
=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>о</span></s=
up><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>С</span></s=
pan><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>.</span><sp=
an
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-fareast-language:UK'> </span><span lang=3DUK
style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-fareast-font-fa=
mily:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Не
заморожувати. Оберігати від падінь, ударів, впливу прямих сонячних променів.
Зберігати в недоступному для дітей місці.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Упаковка.</=
span></b><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'> По 12 мл/2=
00
доз у контейнері; по 1 контейнеру у пачці з картону.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'><o:p>&nbsp;=
</o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><b style=3D'mso-bidi-font-weight:normal'><span
lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Roman";mso-farea=
st-font-family:
"Times New Roman";mso-ansi-language:UK;mso-fareast-language:UK'>Категорія
відпуску</span></b><span lang=3DUK style=3D'font-size:12.0pt;font-family:"T=
imes New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
UK'>.<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span lang=3DUK style=3D'font-size:12.0pt;font-=
family:
"Times New Roman";mso-fareast-font-family:"Times New Roman";mso-ansi-langua=
ge:
UK;mso-fareast-language:UK'>За рецептом.</span><span style=3D'font-size:12.=
0pt;
font-family:"Times New Roman";mso-fareast-font-family:"Times New Roman";
mso-fareast-language:UK'><o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal'><span style=3D'font-size:12.0pt;font-family:"Ti=
mes New Roman";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:UK'><o:p>&nb=
sp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><b style=3D'mso-bidi-font-w=
eight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Виробник.</span></b><span lang=3DUK style=3D'font-size:12.0pt;font-fami=
ly:"Times New Roman";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'> ТОВ «<span class=3DSpellE>Мікрофарм</span>».<o:p></o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'><o:p>&nbsp;</o:p></span></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><b style=3D'mso-bidi-font-w=
eight:
normal'><span lang=3DUK style=3D'font-size:12.0pt;font-family:"Times New Ro=
man";
mso-fareast-font-family:"Times New Roman";mso-ansi-language:UK;mso-fareast-=
language:
RU'>Місцезнаходження виробника та його адреса місця провадження діяльності.=
 <o:p></o:p></span></b></p>

<p class=3DMsoNormal style=3D'margin-bottom:0cm;margin-bottom:.0001pt;text-=
align:
justify;line-height:normal;mso-pagination:none'><span lang=3DUK style=3D'fo=
nt-size:
12.0pt;font-family:"Times New Roman";mso-fareast-font-family:"Times New Rom=
an";
mso-ansi-language:UK;mso-fareast-language:RU'>Україна, <st1:metricconverter
ProductID=3D"61013, м" w:st=3D"on">61013, м</st1:metricconverter>. Харків, =
вул.
Шевченка, 20. </span><span style=3D'font-size:12.0pt;font-family:"Times New=
 Roman";
mso-fareast-font-family:"Times New Roman";mso-fareast-language:RU'><o:p></o=
:p></span></p>

</div>

</body>

</html>

------=_NextPart_01D6175F.3B6735C0
Content-Location: file:///C:/68135086/UA105300101_E2BF.files/image001.emz
Content-Transfer-Encoding: base64
Content-Type: image/x-emz
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------=_NextPart_01D6175F.3B6735C0
Content-Location: file:///C:/68135086/UA105300101_E2BF.files/image002.png
Content-Transfer-Encoding: base64
Content-Type: image/png
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=

------=_NextPart_01D6175F.3B6735C0
Content-Location: file:///C:/68135086/UA105300101_E2BF.files/image003.emz
Content-Transfer-Encoding: base64
Content-Type: image/x-emz

H4sIAAAAAAACC+2dC7hWRdXHD35KKClI3hEDxEtGgDeoRBMpSBSUVFQgDa/wST7FYwgJecPQ0MoL
hSSaeMMLIJfMFKLEa1oildqHqBVg2gUtRbNsf+e3db3NmTN7z+z9zrzvPoe9n+ecua1Zs2bm/87e
M7NmTZuGhobxjX/y3NLoWSSBRnfCTg0N5+7S0ND1c0MHNTS0adjliTYN/9MY30ahwXt424aGaY0J
B23R0HCYlvjCDe0a+j+/ZcPwRrpZj/83US9LWN7a6Fnc+Hds49++jX+TGv+6fpCva8NTDZJOmvjb
NHRtDP2XLg588O+9996LWuPfiBEjok2bNrXKuuXtr0svvTRq7PbooIMOKtulxrhv37591L1797Ld
G9v9oosuinHYrVu3sj1qjEPGjmXLlsXtz1hw5JFHbrZ9MGbMmLgdPvaxj222bZD3XeIz39e+9rUK
HsHkhAkTNqv+2GeffeL6f/7zn9+s6u0TQ1l4/ec//0ltZ8YDcKj+zZ49OzVPlvKLSPvLX/6yUl++
E4soY2uUKfrgSarbmjVrKv2i4hH/ww8/3Or66YQTTqjUd+3ata2ufkn9XO94xkT1SRojr7766kr/
6Hgk/Oc//7nF99mPf/zjSh1POumkFl+femMra/k6FsFlEh4HDx5c6SsTHnfeeecW2X9//etfK/Vq
06ZN9Pe//71F1iNr3xeN3oRFGSd1Wd95551Kn5mwKHGHHXZYi+jL119/PQJ7Ivfy5ctbhNx6v7SW
sOAuydXruXDhwkrfSR+Ke8EFF7SIvly0aFGTOjzwwAMtQm69L1pbOAmDarz+zj7zzDOjyZMnx/33
4Q9/uEm/nnjiiYXs13fffTfafvvtK7K2bds2euuttwopa2vDmEt90t7PKhbx63hU+ffu3bvSx4yR
ffr0KUQf33TTTU3kQrabb765ELKp7Vf6399H1zFnCye12/HHH9+k3xkvk2h9x3/7299uUrZ8M+Ay
FvKd67vMkl8YPYws42PaGDlp0qRmmFi/fn0QHHzkIx9pUtZOO+0U/eMf/whSVom7MLhLa1fbmKim
J72zb7jhhiYYYWxasWKFV4wccsghcRnXX3+9V75pbVOmFRuPYNPURz//+c+b4dHXniFjH/geNWqU
sWyTPGVc7XHkq82zvrNN5W7YsKEZHidOnFg1flatWhXz/d73vlc1L5PcZVzxcJsVj0nvbH3N59hj
j60KQ/fdd1+MxR/96EdV8SkxVzzM2fpE/Ua0+ZPwqK/5fPzjH8+No+nTp8dYZHxMkp39lNawP55U
v8053oZBPd3UVqruC9977dq1S8SSKb/E9erVK9p6662teWfOnBlts802VjrhW7otZ5z08c5mrwYc
qn8vvviiM15EV+icc85xznPqqadGZ511ljN9icmWg0l9DEwLm97Zc+bMaYJFcOmyH3zLLbfE+Vi7
TsILWD/vvPOapfO+ppw//elPzdKSeJXxLQOTafgzpen9unLlymZ4TJsXCw7ZQ/7nP/+Ziqf58+dH
rD/qZRJGJ/GKK64wppnoy7iWgces7+y8/fqvf/0r2mqrraItttjCikMpQ/QRTWdq77zzzujQQw8t
8dj425T2ag1uVjya3tm2dliyZEk8hl577bWZ2w7M3Xbbbc3yvfrqqzFPW9llem3wquKo2jY3vZdd
42xljxw5MsZNljmOynPWrFnRwIEDm+ERmo9+9KMRZ6xU+tJfe/zpWMkzZqn9pvNzDaeVi34Netf9
+/dvgpfnn3++yffmwQcf3CRdlUv8rCE9+eSTzeg4a3rHHXc0i5d8pesPm66YELo0bNj6RR1rhZ+L
m1QmGGH+y9gmZY8dO7aCw1//+tfxuLbXXnvF+9PQrl69ukIrecS9/PLLo8985jPN0s8+++yINKEr
3frhz4SXavrDxM8WZyoP/XHwxfcd6WeccUYcPuKII5rg5g9/+EPUoUOHOI6xjzxpOjxg9xe/+EUT
Hpdcckl07rnnNokzyVTGpeM073hkwwfpedvehbdKYxobOcMldkN++MMfxhgbMGBAokzMt2XvjzET
TDKnzluHMl867qR9QuJPxQh+E05EjjQ3q4x6OX379q3Y8UHHwmVdh73vBx98sII/9lxM699pcpdp
bhhU20nHTOiwjhVVliR/VjyqfE4++eRo0KBBkYyJM2bMqGBMpdP97BFOmTKlQvurX/0qQg9cpyvD
2TGX1mah8WfinyZPUpqJT1Kc8FiwYEGMIc4W8r7NcoZ+6dKlzc6A8Z3Ino/wL12/WKQ96/Vk7UtX
OdXxl3ERHH7yk5/MhSHe7c8880wlL/Pwiy++uBLOWod603/lK1+J24M2wV5rveUxle/azyHpVAyZ
ZMwbt++++0a8r/Pmx04fc3LJzzv/qKOOqoQlvuiu/C5Vu7jo0OXZkwpd15A4y8vbR51vvPHGqBr9
W2R45ZVX4vGE9R/C7Lew7+JDvtA8wBrjIH8m/bf7778/4vsjtBxZ+efFTOh81Y6Z7L3Mmzev6vbG
tumwYcNiPnx/0r/YlMjazrWgV9f1O3fubJUR21pPPfWUla4WsksZoXFVLf+8uNx2220jGdekrnld
+o3zs+Tnm5KzYnl5+cy3cePGeO1KxsGs9nDZD5g2bVoh6iLtUi1eapVf5HV1t9tuO294lPXwxx9/
PN638YVz17qodAcccEDlPQwO1TVSlc7Ff/vttyfqg7jkD0ETCk+6rIxzvh6dtyncr1+/CF0yU1qe
OM4U0v/o6ubJnycP9jRk7BN36tSp3spft25d9KEPfcgbvzx11PPUEiO+ytL5UKcHH3gw6rzzbpW/
vgcdXNXcWm8nwkOHDo3Gjx/vvf/4Hu3Zs2cz7IHB0Oud3InCuG+qbz3i9L51Cef9pqN+oZ699947
nmcI/xHHnRCPZb/73e+8tPW4ceMiynDto/3228+ILxnndLdeuhfY2MD+lWu9QtNJ/6W51eBPl9/n
e1tk5nzAN77xDQnG7qqnV0WdOmwf+bCFy9qxy3xV6rrHHntE2B4Acy+99FJh+lrkU93vf//7Ebbg
1Lh6+pt04gcBn/gz1c03JsELOt76c9qpY6J2jd9Hl112We72Zg0TfQxTPUxxrL9/4QtfiOmZixdd
R5y5WpFsqtOHofFn6jcdO3nD2HZirdH0vL3p7Wj3XTrH4xS2TkxyJMW99tprcb7TTz/dOR/nCvfc
c88KfdeuXaua/ybJ5jt+xx13jH77299W5PbNPws/+rEeeERGlwedQ+bK+veWGv7iF78YtyX8Rp88
KuK8oDwL5i+I9ureI87PeQSXtpG9DdZDXOj//e9/x9+q+jjKeS9XHi7lhKJB3+Q73/mOU11DySB8
6Tcdj+r7VOh8ufQdelzoIKqYSvNjWzStfPZPnn766Zhm7QsvxHPspYuXCCSjq2ZcFXXedbe4vJdf
fjmVFzplrOkgZ1qZkjZ8+PCYL7ZSJE5c5gpXXnlls3hJ9+liF0NvQ1cb/nPnzi3MOqSOx0onKh4d
r2ntqGJZzdelS5dKe3HexOceB/duqXu0iH7EYQOi/z17XKUWs2ddH+3YaYdYBtO6pMjnih/m2vR/
Wp/zOwp5d+Kjjz5aaVN+F2n9kpbGGXLqEsp+cFrZehodJrhRsVTpyA88QqPnJ6w/Ou3o0aPjsyqm
vL7iPvGJTzTpD2S6asaV8Vi56a1NsYirn1kdhztu17HSjzKmuOjpYj8S+vbbtI/5bLDYf2bMDHGv
g3o/1+9///sm9c7bnoyvRdB/p6MEP3GnpfwTOlz1kfiktmDNNfQ8k71YfV0XGdevWx9j55677q6I
PGXyBXEc+hHoRgomVV1H6oLNE0nD7dihY5zv2quvccLA4sWLo09/+tNOtEltp8azNyjysHetplXr
R5fpzTff9Mozj0x0kuCp0mEOHpeyBLfsuf7sZz8LWle+ga65pjlOpCpHDR4Ssf6jPjJ+7rFbl+iO
xrmL9LW4vMMP6L1/jEH2ftgDcqm30LzQ+C27++67Z8ojeVWX7xuRqbXbqaJ/suBRaNX20v1qn+Nn
j+3CCy+sul/0ctQwY9spp5xiLEPkmXntdTG22J9TH+HD2tG9CxZGhx1yaORj/KEccKTfb4StKubi
gjFxjznmmPgsLrqJEodbr70baZdauvQLGJOxTO2nJH+SfEn02JZ3sfWQxNc1Pu1cgtQPnDHW3Tnv
zlhcl9+Xa/kmOmz2bbnllk3wBcb0+Qf7OOj6Cg6feOIJ42/LVEZrikvCUFq83ofS10l5ZJx4++23
g7axvv6n95Mq5+iRo6Njjn5fz1an8xnmXct3pE+erZlXEobS4gWPav+m0ZPG/Ndk58Zn2372s5+1
3kOkynzH7XfEYyXf8j7lUHkdd9xx0VVXXRWMv1pWa/DbcOQrnT1d5hwh24zvr+eee85ahopJbNDz
/p5zwxxrvjyys0aU9fuP9VGf8/I8ctcrjy+82fiwJ4MOTsh6ctZlxYoVTmWomESmE48fEQ0a+Dmn
vFnqgD3eIUOGZOLLGnsahpm3s77F2ia6TVnkKTqtDUe+0jl/wrp4yPbApreLffAkGdjrZqxkbpFE
kzX+Jz/5Sbz/niUfOnJ33313bK9P5jc2V86cZSmniLS+8JbER+rMWm7odxDr19iwlzLzuOydgckn
Hvczv0UfOIs+l9jrBX/oq9nsmOt1ZM5I3pY6P0/CUbXxvA/Vtnr22WeDn11Gt/Smxvul1XLr7Ucv
A3y88cYbqXJddNFFMR12UqvdJ+GeEt2GoEs76PtTLnl801SLOz2/jkORl7051uEkHMLFBgCYrJb3
5PMnWfGTpQzO3Sftl957770xDn2ezQf7/Aayrq9hj9Cka5KlrtXS6niqJmyTpVOnTl71evTysH1b
7VmQ4cOOjSaeN7FqTKuysQ51zz33NOPJuQZwE8KuJLZi0HtS5Ujzs/e/6667OtOn8aomrRr8Sd6k
MVGXCx0t7Nbp8b7Cd911V/Stb30rN/8+PXtHN83x/77HboRqu5m+B4c2vc5q2oW5Y5bfJutSX/7y
l3O3XTWyqnkFU3ldlZfNjz1adKVsdHnTmZPmwSPvNeYw998XRjbmWWCSesk5bvZQ89YzRD7sS7EW
EIJ3Fp7gUF2Ly4rLLGVxjo07sLLkyULL+Jh1L+TFxnNgYPHpgOM272re2XJ/g64Xl6WOIWj/8pe/
xOM1+7oh+GfhKXjMi8ksZaHDzdwvS54stHw/ZrEh9/hjj8VYtOnVZpHBRMu8dYcd3tdNz/IONfEK
EceYnaaLEqLMJJ7gUP6yjo3QJ/E1xX/9618PukfDmvvs2bOdZJp789wIvUfXczKm+rjGiV20rGdz
XPlXS4cuYJY7bKstLy2/YBGaPA/50/iraZwJCPnNzBk5lzuIrph+eTTsqKHOcqt1yOtn7sqeKfZ1
i3ZHNrYLfvCDH9S0PZLaMQ2P5CE97cmCR+5wSdKZTZIvSzz747Zz1uPOHhuddcZZzdpe6pmlvCy0
7E1hX5c83JVUJDu7rH3q9+dkqZtP2jQ8CtZ84ZH+CHG+SdqDd05auzImTr1gaiIWpb7Cz6fL71A9
T8HavU/+Jl58F3Lm1pQmcXK20HRPrdDU0lXxiF99pH/UON0vNC4yM888+uijU9vHhU8SDfpmSedo
+x3YN7rumuuala3WJ4mvj3jG7jSdnbxlsJ7AWmbSn80eAfZxu3Xr1qxd8spTbb40PNJX8E97suCR
vbGsNlyz1E+11y752AtmPWf+PfObtDlyy5OlDsI3q3vrrbd6+S0yjqnnH7DJklUWlR65surDqfl9
+1U8wlt/THEqTZa+BI+DBw+uqv2S6s8clrMBavqa/1sTY/HFtWsr8SoOqUcW+VXeWf2sOVZjX//S
Sy+tjIE+zz8wbnMPSNb6hKJ3waPeh3nxiC5YiO94+PK+UvdmVj60MsYi+lqCOVVu/KHa1MSXc6rc
TWxKS4uTe8V69OiROW8aX0nju7ZIa6I2PEq63pdqWOpmc1mLOeSQQ5zblTuy0AFM+jaSeM7lfepT
nzLqpqhyit8mZ6h0zhqyH+TKH71Jl7sWXfmZ6Ph+KpKOueBNZCWsPpKuxul+yevi8k4VHNlc7MCh
z+ryoO8na49i4wn+rGVInVzkC0mDXYTly5db8fjII4/EbYROZEh54M055Gp06n3LJ3gTvtJ3KgZM
cWq65E1zbTxUfln9lMvcVfCt2sIgXn2Pp8kYOo21rrR7tClf3s9gMrQ88EcvLW2NrBYyqGXoeCRN
f2xYIo+NRufpK6zWxeT/6le/Gk2fPr0mfWsqX43jnBbvYH43AwcObCYTe/ukce+Bmi+kn28dbOSG
LCMLbx949IWtrHxc6gkemZu60IamYX89yVY3eu1gUe6ADy2L8Me+EGdJJFxv1wWPWXFSC3rXduPM
Yehztq6yoPOo2nOWfHz3gsW1yrqUpIV2WwIe9XevYLYWOHMtA5lc+godhjSboS48fNH88Y9/jLg3
zMSPMTzkXoGpTOKKiEcwoMqr45F0Uxzx9Xpc8cgcNeS5ALXdXPzo9iTtaXJXVq3tyqedNXOpj28a
wZnOV8cZ6UV7dJlNYfS7sFthSqtHHGe41LkzdiZkPRp/rb91izi/Bmd63+jYI12wq6fVK6zLbArT
v0WwQyyyoWuonhFHB0T00G677baav7N79+4d/E46qbuLKxjTaXWMyftRj69nWGTSZVfDnKUKoVej
lpHFz5kNdX7FGvmyZcvi8YAz2qb5Thb+WWk5p1C09XAwpddDcCp4k77X4yXdt+tSjsiky66GuS+h
KLr4yMVaKHd4iYzsacv3JPcYd+jQoZImNCFd9m9tOswhy1d5c2+Q9Lsaj1/iVZwJjRoXym8qXy/L
BY/f/e53Y31skb3eLmdyxVYwOj98T4pM4JL9egnXwi0KHtFVwF6E9Lup7nr/qzSST6ch3gUn8Ep7
hI+NRpXJ5AePZ555Zk372CSHxPFO5lyXhFX79KxL+7B/L7xdXHTg1PmVS54QNOhxiv5BEn8dC0l0
eeN1/mrYBY/Q28pmv3jMmDFWOhsfX+nYzGftm3eTzpP3Zq3PnaI/FNI+sF5HU5hvfO7WM6WpcSo+
8LuOeyqPNL/OXw274NFFHvbhQp4hS6tfUtpuu+0WrV69uln7Y1OFNZ+kfL7j999//9hOgW++WfjJ
+Z1Vq1ZZ601/q49L/2eRReWt+13wSB5beazt2c402Xj4TuebjbNWOl/ODVRrv1LnaQozb2KMLsJ3
DL8/VzlUPPrGIu2U9rjg0UUmvh9Dnmk09bctju+Het2nKrasbN9qtjr4SGdM5HdRlLONaXgkjTrb
Hlu7FG0+g7yXXHJJULsISW2C3Rb6n/uWkmhqGY9uNt+OtSwzrSx1/DXhziU9jT9pzGe+9KUvFabO
yMTYdOSRR9ZUJrHjzB6Qrc1qkc7Z51qvJdjq5YI3E07VOFsZ6BzKfe022lqlc+Z5n332qSkuuNP+
/PPPr2mZae0JFk02WtPy1CJNxZbud8GrTUbmB+p+iI2+FunYw2WdpRZlUca0adMi09n0WpWvl8P5
Ee6Q0OOLENYxmDVsq0NoGy228pPSObfAWbWk9CzxrB8k3V3B/dh8M9ZD19dUh3feeSeWJ6SdZFO5
rnG2MTANn+S1lQMek84I2PKGTGfd28e8on379pX9R5O8nHcvij4y8o0bNy46tfHud5OsRYirBo9g
1VaHefPmReh02ehqnc43bRbbqbp8N998czzOpJ1V++lPf5qoj67zq0VY7AOHsN/vU/60MdCWZpMj
tA0rW/lJ6eicTZgwIdfvhP0d3sHYiEniTzzr7jNnzkylScvvO431/gsD34PuQ2Yb5tLSbeVjM6jW
ays2mUjPY1+KdStw6KJDztiY5V4wF5mroUHHsmPHjoX5baTVpZp3dhpf0sDjoEGDCtcO3Ofmal/q
pJNOinGITXxbfSWd3yC6nxKut0tda7EX6queaWNgWpqtfOYMWfrRxs9X+muvvRa1bds2ES+MJ4yF
/HGHdpZy+U7j3rla2EZ3kYs1YO4/d6EtCk3eMdImP3hkX8pGV4909CDlHjnOugr+cFmftH0fJsmM
jfbx48cXps68p4t0JiKp3fT4PJjUeehh7pXlu16PL0IYPXH6CvxxX70vmTgD8Zvf/MYbv2rk4nxn
Eb/fXeuUFZM2vtiWqrWOq00mSR85cmTEfe0S9uGyP520Nu6DfxYeontcJHssWeQX2iyYlDxJLngs
0l6ZKidrPr7PhmN/2GZDTZUhpJ97JGqpXxyyLmlzGDXNJgP6fpwxttHVI33u3LnR0KFDvcmGLSre
/dXen+2jLdgLRZaNGzd6q58Puarh4TJO2vg/+eSThcUjv5WePXt6669Zs2YVxjY9e2LYTrL1T0tL
t2HSVh90u1zX+Wy8SF/eaN8WXbGs93aaeL/66qsRNntMaXniGGvBZJ68PvOsXLkyl610nzKE4lUt
HtGJr0bXEBt5vHfUP9ZmxK6oxKPTlacNOHP8wgsv5Mqrlwe2X375ZS+8dN5Zwsynqtmbz1JWPWjV
70Xdb5Pn0UcfzWWDBLvzgjX1jHRSedjRgz7rnghrPqxJJfF1jccuUBHmbQsWLIi6dOlSdX1c611r
umrHR74fsUmcRe6pU6fG2Mpzdzx9AS5ddRtZ86lG54E7vymvKGcoeRcV4axYlv7OSquPiWrYxov9
j/32288Zj6eddloT+xE2/qZ07MODEfadTelqHOvFefdSWCuiHOycqjzr5Wd/uqhrGb7apNrxke9H
bG66yIPtMVdaF37YLgMvr7/+emL58+fPj7irxIWfSsMZ3iLp7yDbLrvsUhjbVGpb+far46HuB69p
5aFb4PK+5s407qhO45UnjXcxmEyy0fvwww87yaeWzf5br169vMuqlpHVz921LjZPsvItIr2OQTVs
wyNzV9WGmKl+t9xyS7T11lsbbeqY6PPEbbvttkZdbdZ8KNuVJ7pzRdkPVGVmH16990dNa21+FX+6
Pw2P0HKeCX3qpDbh7hXGL87KJ9H4ipex8sADD6yUxbzH1cYe42IRz+Vhk6aIOn2++k3no2NQDSfh
kXge8Mi9czpPCfO7FnvJEhfKBfPMv/lO5Tcgfy76jSNGjIj69u2bWI9QMrvwpX03l7GR9hBsqThU
/aY2k3T2dJNszvLeY8/flD9UHHqyovPoWgb6jHvvvXdN5XSV7cYbbyzk94Or/HnosuJRsIj7xhtv
GPeuWPcLpafLfW/slcj4p7tZdHqwb5N0Z02etvSdp3///hF6Ib75FplfFjzqtNx/vdVWWzVpL3AI
Rkw271zbATtVOs5cw6721hYtWhSXUes75FzbgL0G7tNxpW8tdDrG1PEPv9TTREccuv/ohsr5X9ap
0ce22VZasmSJE+Z4n4oMqsvasAmjLvYJGGPJy/65yrNI/gEDBkTf/OY3CytfqLYy4UzFpJSrxql+
sCe4wBYnD3qirJmRl29ISXd1sQsh5Zpc9BqSeLnsx6CTVCRbdHod0SWuRk9F59eSwjY8kk59bA90
wov2TMKLLd62hyNrSEl8GHfT2h+bE0U984PcfP8yL3v33XdT65FWx5aeZsNannTWoZMwkxaPTRy1
PYcPH27l07179wgbjGq+JD+26NDVTUqvZzxruZ07dy6kbLVsFxnX8uAuKQ+6h2m485nWo0cP57ut
sTPPnlEt29dWFt8OtAe6TzbazSU9CVdZ45nbcD49L96YU3Jfimu7My6q37Bqucy1VPtKrO0Uyf4X
+63Im7an4NoOrY3OxxiZBYecReVhf48+GT16tDMGXdt+xYoVTX4XvPtd84amk7banPZesrZp1rFQ
pxc7dTJGsTaJ/rfpwXYm41cW/cms9SkiPfZraZ+89teKWKdQMvkYI03Y0+Ows0KfsB8Wqi5F44t9
Fuqs3mdXNBmLKI+OnWrD1FFwjh9bdfQLNsiKWP8QMomOR2s/axCi7eDp4zHJxr2CrK1Vs5do4lvU
uDVr1sS/vaLqDhW13XS5ZDzLg0vy6vwkzFpvkea3IlcIF50S3gOcKQ/Bf3PjmRWTLu3TrVu36LHH
HmvV/SP7+IcffnirrqdLf/umScNk2jiYJAfjRV67i0k8ixQvNp/LMfG9oL9F/b2dFYuu+mOTJ08O
Wo9Q2GVNi99aUW0Phqp3S+Q7ceLERB1ytT7so8jdBvSt7a8oeqrcE4esnK1V61P6w46RedsX/QV0
cvLmN+V75ZVXYl1VFbPYEjHRhozjrBjfxCHLKHn7xTXf9byvQ7YrtnUEm3/729+ClkU90DWmvBkz
ZgQvK2S7bY68RXc2pO4KdlHQI+csIzhhjhuqrdGHo4xa4D5UHUq+78V2A+hH7Bf6bg/upTr33HNj
vtx/EcrWCXrr2AP0LX/Jz+872bU9X3rppcp7deHChd76FVs+6n3PnO13uWfLVW50cPgt5bVD6VpO
SVcfXG7atCnW7aGP+eMsXd6+WLZsWWxrSfJjswee2CKQuGrcYcOGxfx8z8mqkanMGw63coe0YNPk
gq3LLrsseuSRR2Ib7ugHYT/ZREvc+vXr43P01113XW5MMr7Cq4j315Z4DIdHW9ty9xtnqnXs8Y34
0EMPJeJN9u2y3LEgYytl7bnnnom8bTKX6fXDS9Hb/vTTT2+GZR3batjFfnTR61zKV/4eSgyUGCgx
UGKgxECJgRIDJQZKDNQHA6JzWbZ/fdq/tbY7OpNZ9CRby12lrbU/W3q9wKOpDtivVddXxL+52vMy
tVEZ5//dkITHpP0Y9CTLfvDfD2Wbvt+mSXhET0vGRNVNskNetmeJUR8YSMIjvLGjomIRf7t27crx
sbFtfLR9yaN5O6bNZfT7hAWbm7MNzhJDzTHks03S8IgNXMGg6m7cuLEcH8oxMggG0vDYr18/Ix43
bNgQRBafv7OSV9hxLFT7puERnX91XBR/qVvTMvs6FIZ88k3D45AhQ4x45H4GnzKUvEp8u2Bg1KhR
Rjw+++yzJR7L78eaY+Ccc84x4rGaczQuv4OSphwvTRiYMmWKEY/qfVnYIVm6dGnNfysmecu41o1j
7nSWOUyS26tXrxKL5bs7CAYmTZpkxZ+Oyzlz5gSRpRzrWvdY59q/ffr0ccak7V7TtLm7qzwl3eaN
yzfffNMZjzY7kCUeN28s+RpLsGmiv5dNYezp2cosMVli0oYRl3S5+8KEQ+LGjh1rxSLlpOkPuchR
0pR4Fgz07NkzcZx87rnnnPDI+FiOkSWmBFPVuOvWrTPiEbtkrnxLPJZYdMWKC93s2bObYXLx4sXO
eHQpo6QpMSsYcHmXnnLKKRVMlvabSuwIdkK44FGeNGzKnQpFuS8hRFuUPIv3WxN86thctWpV1KlT
p0zvaZ1H2d/F6++W2icyhmaRv8RjPvxt17igtkPjH0/Hxj/8/w9v/uKIGMkBAM==

------=_NextPart_01D6175F.3B6735C0
Content-Location: file:///C:/68135086/UA105300101_E2BF.files/image004.png
Content-Transfer-Encoding: base64
Content-Type: image/png
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==

------=_NextPart_01D6175F.3B6735C0
Content-Location: file:///C:/68135086/UA105300101_E2BF.files/image005.emz
Content-Transfer-Encoding: base64
Content-Type: image/x-emz
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------=_NextPart_01D6175F.3B6735C0
Content-Location: file:///C:/68135086/UA105300101_E2BF.files/image006.png
Content-Transfer-Encoding: base64
Content-Type: image/png
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------=_NextPart_01D6175F.3B6735C0
Content-Location: file:///C:/68135086/UA105300101_E2BF.files/filelist.xml
Content-Transfer-Encoding: quoted-printable
Content-Type: text/xml; charset="utf-8"

<xml xmlns:o=3D"urn:schemas-microsoft-com:office:office">
 <o:MainFile HRef=3D"../UA105300101_E2BF.htm"/>
 <o:File HRef=3D"image001.emz"/>
 <o:File HRef=3D"image002.png"/>
 <o:File HRef=3D"image003.emz"/>
 <o:File HRef=3D"image004.png"/>
 <o:File HRef=3D"image005.emz"/>
 <o:File HRef=3D"image006.png"/>
 <o:File HRef=3D"filelist.xml"/>
</xml>
------=_NextPart_01D6175F.3B6735C0--
